Spain Biologics Market Size, Share, and COVID-19 Impact Analysis, By Source (Microbial, Mammalian, and Others), By Product (monoclonal antibodies, Recombinant Proteins, Antisense & RNAi Therapeutics, Vaccines, and Others), By Disease Category (Oncology, Infectious Diseases, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others), By Manufacturing (Outsourced and In-house), and Spain Biologics Market Insights, Industry Trend, Forecasts to 2033

Spain Biologics Market Insights Forecasts to 2033

• The Spain Biologics Market Size was Valued at USD 12.1 Million in 2023.
• The Spain Biologics Market is Growing at a CAGR of 11.67% from 2023 to 2033
• The Spain Biologics Market Size is Expected to reach USD 36.5 Million by 2033

The Spain Biologics Market is Anticipated to Exceed USD 36.5 Million by 2033,Growing at a CAGR of 11.67% from 2023 to 2033. The increasing healthcare expenditure, aging population, and demand for innovative treatments are driving the growth of the biologics market in the Spain.   

Market Overview

The biologics market refers to the industry of production, sale, and use of drugs derived from living organisms or their products, including monoclonal antibodies, vaccines, and recombinant proteins. Biological products comprised of products include vaccines, blood & blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. The growing prevalence of cancer, genetic diseases, and autoimmune diseases, along with the approval of disease-modifying therapies, is significantly escalating the market for biologics. The use of AI in personalized medicine for analysing patient data as per individual need for biologic therapies is providing lucrative market growth opportunities.

Report Coverage

This research report categorizes the market for the Spain biologics market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Spain biologics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Spain biologics market.

Driving Factors

The increasing healthcare expenditure is contributing to driving the biologics market. Health spending as a share of the GDP in Spain amounted to 10.4% in 2022, down from 10.7% reported in 2021. The increasing use of biologics therapies for various conditions in older populations is driving the market demand as they require careful consideration and increased risks of infections, malignancies, and adverse events. Further, innovations including targeted and effective relief contribute to escalating the market growth.

Restraining Factors

The concerns regarding the growth of biosimilars, government cost-cutting measures, and ethical concerns of animal testing are challenging the market growth.

Market Segmentation

The Spain biologics market share is classified into source, product, disease category, and manufacturing.

• The microbial segment dominated the market with the largest market share in 2023 and is anticipated to witness significant CAGR growth during the forecast period.

The Spain biologics market is segmented by source into microbial, mammalian, and others. Among these, the microbial segment dominated the market with the largest market share in 2023 and is anticipated to witness significant CAGR growth during the forecast period. Microbial source biologics include the medications derived from microorganisms, often using biotechnology to produce complex molecules like proteins.

• The monoclonal antibodies segment held the largest market share in 2023 and is anticipated to witness significant CAGR growth during the forecast period.

The Spain biologics market is segmented by product into monoclonal antibodies, recombinant proteins, antisense & RNAi therapeutics, vaccines, and others. Among these, the monoclonal antibodies segment held the largest market share in 2023 and is anticipated to witness significant CAGR growth during the forecast period. Monoclonal antibodies are used in medicine specifically designed to target and bind to particular proteins, which are used for treating conditions such as cancer, inflammatory diseases, and autoimmune disorders.

• The oncology segment dominated the market with a major market share in 2023 and is anticipated to witness significant CAGR growth during the forecast period.

The Spain biologics market is segmented by disease category into oncology, infectious diseases, immunological disorders, cardiovascular disorders, hematological disorders, and others. Among these, the oncology segment dominated the market with a major market share in 2023 and is anticipated to witness significant CAGR growth during the forecast period. Biologic treatment includes the use of the body’s immune system or targeting specific aspects of cancer cells to fight cancer.

• The in-house segment dominated the biologics market with the largest market share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

The Spain biologics market is segmented by manufacturing into outsourced and in-house. Among these, the in-house segment dominated the biologics market with the largest market share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. It includes the production of biologic drugs within the own facilities of a pharmaceutical company, rather than outsourcing the manufacturing to a third-party contract manufacturer.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Spain biologics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AbbVie
• Johnson and Johnson
• Bristol-Myers Squibb
• Amgen
• Merck and Co
• Novo Nordisk
• Eli Lilly
• Roche
• Sanofi
• Pfizer
• Mylan
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Spain, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Spain biologics market based on the below-mentioned segments:

Spain Biologics Market, By Source

• Microbial
• Mammalian
• Others

Spain Biologics Market, By Product  

• Monoclonal antibodies
• Recombinant Proteins
• Antisense & RNAi Therapeutics
• Vaccines
• Others

Spain Biologics Market, By Disease Category

• Oncology
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

Spain Biologics Market, By Manufacturing

• Outsourced
• In-house